Drugs / Furmonertini
last change Nov 2025 re-read 2 minutes ago

Furmonertini

Developed for
non-small cell lung carcinoma

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07229729 Comparator Nov 2025 → Oct 2026 expected non-small cell lung carcinoma Shanghai Hengrui Pharmaceutical Co., Ltd. Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Furmonertini ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229729